USANA stock touches 52-week low at $30.28 amid market challenges

Published 12/02/2025, 15:42
USANA stock touches 52-week low at $30.28 amid market challenges

USANA Health Sciences Inc (NYSE:USNA). shares have reached a 52-week low, dipping to $30.28, as the company faces a tumultuous market environment. According to InvestingPro analysis, the company maintains strong financial health with an impressive 80.86% gross profit margin and holds more cash than debt on its balance sheet. This latest price point underscores a significant downturn for the health and nutrition company, which has seen its stock value decrease by 37.8% over the past year. Investors are closely monitoring USANA’s performance, as the company navigates through the pressures of a competitive sector and broader economic headwinds that have impacted consumer spending and investor confidence alike. The 52-week low serves as a critical marker for USANA, reflecting the challenges it has faced in maintaining its market position and shareholder value during a notably difficult period for the industry. Despite current market pressures, InvestingPro analysis suggests the stock is undervalued, trading at an attractive P/E ratio of 11x and EV/EBITDA of 2.1x. InvestingPro subscribers have access to 10+ additional exclusive insights about USANA’s valuation and financial health.

In other recent news, USANA Health Sciences has been making significant strides. The company recently appointed Dr. Kathryn Armstrong as its new chief scientific officer, following her successful tenure as executive vice president of research and development. Dr. Armstrong, with her extensive scientific background, will lead a team of 150 professionals, focusing on product development, regulatory affairs, and quality control.

In a major development, USANA has also acquired a 78.8% controlling interest in Hiya Health Products, a firm specializing in children’s wellness products, for $205 million in cash. This acquisition is expected to immediately contribute to USANA’s 2025 adjusted EBITDA. Hiya, with net sales of $103 million and net income of $19 million as of September 30, 2024, aligns with USANA’s strategic initiative to diversify its growth.

These are among the latest developments at USANA, reflecting the company’s commitment to scientific research, development, and diversifying its growth. The company’s acquisition of Hiya is expected to strengthen its financial profile and establish a stronger presence in the children’s wellness market. As part of the acquisition, Hiya’s founders will continue to lead the company, leveraging USANA’s international expertise to expand their product reach.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.